Page 47 - 2021_05-Haematologica-web

CUDC-907 combined with venetoclax in AML
day break was given out of an abundance of caution since a higher dosed group from a concurrent trial (150 mg/kg CUDC-907)11 experienced moderate body weight loss (3%). Co-treatment of venetoclax with CUDC-907 pro- longed median survival from 33 days for control subjects to 52.5 days with minimal weight loss (Figure 1D-E). Taken together, CUDC-907 enhances venetoclax activity in AML cell lines both in vitro and in vivo.
CUDC-907 and venetoclax synergize in primary acute myeloid leukemia cells and co-operatively prevent colony formation of acute myeloid leukemia progenitor cells ex vivo
In order to enhance the clinical relevance of this study, primary AML patient samples were treated with CUDC- 907 and venetoclax at the indicated concentrations for 24 hours. Annexin V/PI staining and flow cytometry analysis
AB
C
Figure 3. Legend on next page.
haematologica | 2021; 106(5)
1267